Journal of Clinical and Aesthetic Dermatology

DEC 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/918586

Contents of this Issue

Navigation

Page 52 of 59

JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY December 2017 • Volume 10 • Number 12 53 skin. As of November, 2017, Sejal Shah, MD, and her team at SmarterSkin Dermatology in Tribeca, now offer Vivace RF Microneedling, the newest generation in microneedling technology. * For more information: https:// www.prnewswire.com/news-releases/ expert-nyc-dermatologist-introduces- breakthrough-rf-microneedling-treatment-in- manhattan-300556587.html CONSEQUENCES AND OUTCOMES OF CONSOLIDATION IN DERMATOLOGY DRIVEN BY PRIVATE INVESTORS Consolidation of dermatology practices in the United States has accelerated in the last few years, which was discussed in an article in JAMA Dermatology. However, the author noted that as of 2014, three-fourths of dermatologists still had solo practices. The author stressed that an increase in "investor-owned conglomerates" could eliminate choices for patients in the future. * For more information: http://www. ajmc.com/newsroom/consequences-and- outcomes-of-consolidation-in-dermatology- driven-by-private-investors XBIOTECH ANNOUNCES PUBLICATION OF DATA FROM HIDRADENITIS SUPPURATIVA PHASE 2 STUDY XBiotech Inc. announced the publication of data from its randomized Phase II study evaluating XBiotech's True Human™ antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS). The results have been published online in the Journal of Investigative Dermatology and is titled, "MABp1 Targeting Interleukin-1alpha for Moderate to Severe Hidradenitis Suppurativa not Eligible for Adalimumab: A Randomized Study." * For more information: https://globenewswire.com/news- release/2017/12/04/1219949/0/en/ XBiotech-Announces-Publication-of-Phase-2- Data-from-Hidradenitis-Suppurativa-Phase- 2-Study-in-The-Journal-of-Investigative- Dermatology.html ANTI-HYPERTENSIVE DRUG LINKED TO INCREASED SKIN CANCER RISK? According to an article recently published in JAMA Dermatology, long-term use of hydrochlorothiazide, a blood pressure medication, increases the risk of squamous cell carcinoma (SCC). The authors note that these findings only apply to hydrochlorothiazide and not other antihypertension medications. They estimate that about 10 percent of cases of SCC in the study were because of hydrochlorothiazide. * For more information: http://www. pharmacytimes.com/news/antihypertensive- drug-linked-to-increased-skin-cancer-risk FREQUENT SUN EXPOSURE MIGHT CUE GENE FUSION FOUND IN SKIN CANCER A specific fusion gene, which is the combination of two previously single genes, is commonly found in patients with cutaneous squamous cell carcinoma (cSCC), according to a research team from Kumamoto University in Japan. While cSCC is often benign, it can become deadly if it isn't treated in a prompt manner. The research was published in Scientific Reports in October. * View more information: https://www.sciencedaily.com/ releases/2017/12/171214100838.htm THE STORY OF A NEW SKIN An experimental process to develop new skin for a transplant was successful in a 7-year- old boy suffering from epidermolysis bullosa. The boy, who was born in Syria and had the condition since birth, had lost nearly all his skin by the time of the transplant. The lack of skin was causing deadly bacterial infections. He was helped by Professor Michele De Luca of University of Modena and Reggio Emilia in Italy, who has spent 30 years developing replacement tissues. * For more information: https:// medicalxpress.com/news/2017-12-story-skin. html SERUM HOMOC YSTEINE HIGHER IN ACNE PATIENTS Research published in the Journal of Cosmetic Dermatology found that both male and female patients with acne have higher levels of serum homocysteine (HCY). The study included 124 patients with acne, who had significantly higher serum HCY levels than the control group (n=70). * For more information: https:// medicalxpress.com/news/2017-12-serum- homocysteine-higher-acne-patients.html ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSIS (SKS) Aclaris Therapeutics Inc. announced that the United States Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are noncancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. SKs tend to increase in size and number with age. The condition is more prevalent than acne, psoriasis and rosacea combined. * For more information: http:// markets.businessinsider.com/news/stocks/ Aclaris-Therapeutics-Receives-FDA-Approval-for- ESKATA-Hydrogen-Peroxide-Topical-Solution-40- w-w-for-the-Treatment-of-Raised-Seborrheic- Keratoses-SKs-1011532936 FLORIDA FIREFIGHTERS FACE A HIGHER RISK OF SKIN CANCER A study published in JAMA Dermatology found that Florida firefighters have an increased risk of getting skin cancer. The author, who is an assistant professor of public health sciences at the University of Miami Miller School of Medicine, noted that these results can't be extrapolated to the national level yet since only Florida has been studied. * For more information: http://www. cnn.com/2017/12/13/health/florida-firefighters- skin-cancer-study/index.html DERMATOLOGIST DEVELOPS A MOLECULAR TAXONOMY FOR HAIR DISORDERS Research published in Scientific Reports reports that a group of researchers from Columbia University took a step toward developing a molecular taxonomy for hair disorders. "Genome sequencing is changing the nature of disease diagnosis, and we saw an opportunity with rare hair diseases, since these disorders tend to be poorly annotated in catalogs N E W S & T R E N D S

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - DEC 2017